Zhejiang Starry Pharmaceutical Co., Ltd. Class A

Zhejiang Starry Pharmaceutical Co., Ltd. Class A

SSSE:603520
7.58
CNY
-0.16
(-2.07%)
0.06EPS
142.72P/E
3.84BMarket Cap
Apr 28Next Earn

Total Valuation

CNY

As of September 30, 2026, Zhejiang Starry Pharmaceutical Co., Ltd. Class A carries a market capitalization of 3.84B, placing it among publicly traded companies globally. Its enterprise value stands at 6.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.84B
Enterprise Value6.31B

Important Dates

Zhejiang Starry Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for April 28, 2027.

Earnings Date4/28/2027

Share Statistics

As of September 30, 2026, Zhejiang Starry Pharmaceutical Co., Ltd. Class A has 438.41M shares outstanding.

Shares Outstanding438.41M

Valuation Ratios

As of September 30, 2026, Zhejiang Starry Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 142.72. The price-to-sales ratio is 1.45, and the price-to-book ratio stands at 1.56.

PE Ratio142.72
PS Ratio1.45
PB Ratio1.56
P/TBV Ratio2.16

Enterprise Valuation

As of September 30, 2026, Zhejiang Starry Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 208.03 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 208.03 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 6.31B versus a market cap of 3.84B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.42
EV / EBITDA208.03
EV / EBIT208.03

Financial Position

As of September 30, 2026, Zhejiang Starry Pharmaceutical Co., Ltd. Class A maintains a current ratio of 1.02, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 112.87, indicating elevated leverage, while an interest coverage ratio of 0.41 demonstrates limited ability to service its debt obligations.

Current Ratio1.02
Quick Ratio0.16
Debt / Equity112.87
Debt / EBITDA91.76
Interest Coverage0.41

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Zhejiang Starry Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 1.05, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.49 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 0.45, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 1.71, useful for judging operating efficiency across full business cycles. The company generates approximately 1.37M in revenue per employee across its workforce of 1,905.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.99 indicates how many times Zhejiang Starry Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)1.05
Return on Assets (ROA)0.45
Return on Invested Capital (ROIC)0.49
Return on Capital Employed (ROCE)1.71
Revenue Per Employee1.37M
Employee Count1,905.00
Inventory Turnover1.99

Taxes

CNY

Over the twelve months ended September 30, 2026, Zhejiang Starry Pharmaceutical Co., Ltd. Class A recorded 4.55M in income tax expense. That works out to an effective tax rate of 14.76, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 30.84M, leaving 26.58M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax4.55M
Effective Tax Rate14.76

Stock Price Statistics

CNY

As of the close on November 17, 2026, Zhejiang Starry Pharmaceutical Co., Ltd. Class A's stock has declined approximately 35.76% over the past 52 weeks. The 50-day moving average sits at 8.29, while the 200-day moving average is 9.72.

52-Week Price Change-35.76%
50-Day Moving Average8.29
200-Day Moving Average9.72

Income Statement

CNY

Over the twelve months ended September 30, 2026, Zhejiang Starry Pharmaceutical Co., Ltd. Class A generated 2.61B in revenue and converted that into 26.58M in net income, yielding earnings per share of 0.06. EBITDA reached 30.33M, while operating income came in at 142.94M.

Revenue2.61B
Gross Profit511.74M
Operating Income142.94M
Pretax Income30.84M
Net Income26.58M
EBITDA30.33M
EBIT30.33M
Earnings Per Share (EPS)0.06

Balance Sheet

CNY

As of September 30, 2026, Zhejiang Starry Pharmaceutical Co., Ltd. Class A holds 315.64M in cash and equivalents against 2.78B in total debt, resulting in a net debt position of 1.91B. Total book value stands at 2.46B, with working capital of 38.81M providing operational flexibility.

Cash & Cash Equivalents315.64M
Total Debt2.78B
Net Debt1.91B
Equity (Book Value)2.46B
Book Value Per Share5.61
Working Capital38.81M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-190.02M

Margins

Over the twelve months ended September 30, 2026, Zhejiang Starry Pharmaceutical Co., Ltd. Class A posted a gross margin of 19.61, reflecting its pricing power and cost economics. The operating margin of 5.48 and net profit margin of 1.02 provide insight into operational efficiency.

Gross Margin19.61
Operating Margin5.48
Pretax Margin1.18
Profit Margin1.02
EBITDA Margin1.16

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Zhejiang Starry Pharmaceutical Co., Ltd. Class A paid dividends of 0.47 per share. The dividend payout ratio of 788.58 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.23, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Zhejiang Starry Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.47
Payout Ratio788.58
Shareholder Yield0.23

Stock Splits

Zhejiang Starry Pharmaceutical Co., Ltd. Class A's most recent stock split took place on June 17, 2022 with a 5:7 split ratio.

Last Split Date6/17/2022
Split Ratio5:7

Scores

As of September 30, 2026, Zhejiang Starry Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 1.36, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.36